Company profile · Sponsor
Samsung
Samsung Bioepis NL B.V.
- Pipeline
- 4
- Drugs
- 0
- Patents
- 0
Quick answer
Samsung (E07C417) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (4)
Search pipeline →-
KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Samsung
Non-small Cell Lung Cancer
1 trial -
Byooviz 10 mg/ml solution for injection
Samsung
Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV)
1 trial -
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors
Samsung
advanced refractory solid tumors
1 trial -
Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy
Samsung
Non-small cell lung cancer
1 trial
Frequently asked questions
What is Samsung?
Samsung (E07C417) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Samsung sponsor?
We track 4 ClinicalTrials.gov-linked programs for Samsung, including KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion and 3 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Samsung company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.